Why Eli Lilly Stock Climbed to a New All-Time High Today
Key Points
Investors are excited about retatrutide's potential.
Rival drugmakers are finding it difficult to keep pace with the healthcare leader.
- 10 stocks we like better than Eli Lilly ›
Shares of Eli Lilly (NYSE: LLY) rose to a record high on Monday after the medicine maker announced positive clinical trial results for its next-generation weight loss drug.
Image source: Getty Images.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Successful studies
Retatrutide, Eli Lilly's investigational once-weekly injectable medication, targets three metabolic hormones to suppress appetite, control blood sugar, and support fat loss.
Results from Phase 3 trials showed that retatrutide led to substantial weight loss compared to placebo, along with meaningful improvements in common obesity-related conditions including knee pain, sleep apnea, and type 2 diabetes.
Trial participants on the highest (12 mg) dose of retatrutide lost an average of 70 pounds, or 28% of their body weight, over 80 weeks. Even at the lowest (4 mg) dose, people lost an average of 47 pounds (19%).
Importantly, the adverse events seen during the trials were generally mild to moderate and tended to resolve during treatment.
"Obesity drives more than 200 downstream diseases, yet we have historically treated those conditions one at a time and in silos...These findings demonstrate what may be possible when we treat obesity and impact overall health, and what this could mean for people living with obesity and its related complications," lead investigator Dr. Ania Jastreboff said in a press release.
A rapidly expanding global market
Retatrutide's promising clinical trial results should help to bolster Eli Lilly's competitive position within the $200 billion obesity treatment market.
While Eli Lilly's stock price hit new highs, rival drugmaker Zealand Pharma's shares fell sharply after it reported discouraging safety and tolerability results for its experimental obesity dug.
As its competitors struggle to keep pace, Eli Lilly and its shareholders stand to profit handsomely from booming demand for safe and effective weight loss solutions.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 8, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy.
Recommended Articles
